Search
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalgene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic IndexAlglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.
Mesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalAlthough demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnSomatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues [T28] that regulates the endocrine system. … [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as
Products: STILAMIN 3000 FOR INJECTION 3 mg/ampouleSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. … For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: Sunitinib 1A Pharma 12,5 mg - Hartkapseln, Sunitinib 1A Pharma 25 mg - HartkapselnLifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigational] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawnIn the EMA, by 2015 it was under pharmacovigilance studies for the potential treatment of acute renal failure.[L1314] … Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd.
Homatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedHomatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. … Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.
Categories: Drugs for Functional Gastrointestinal DisordersAntipyrine
go.drugbank.com/drugs/DB01435ApprovedAntipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
Mixtures: Formule L2Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalColesevelam is a bile acid sequestrant.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia